Amgen Compound definition

Amgen Compound means the Amgen small molecule methylthioadenosine cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor known as AMG 193, including any metabolites, prodrugs, isomers, enantiomers, esters, salts, hydrates, solvates, or polymorphs thereof, and any drug candidate or product containing any of the foregoing as the sole active ingredients.
Sample 1
Amgen Compound means a PDE10 inhibitor or modulator, other than a Primary Compound or Secondary Compound, (a) for which Amgen during the Agreement Term has rights, whether by reason of its own conception of such inhibitor or modulator, or under agreement with a Third Party, and (b) was not identified or confirmed as a PDE10 inhibitor or modulator through the use of the Memory Screening Technology. All rights in and to any Amgen Compound shall remain solely owned by Amgen, and Memory shall have no rights, and Amgen shall have no obligations, financial or otherwise, to Memory, under this Agreement with respect to any Amgen Compound.
Sample 1
Amgen Compound means the Initial Compound, and each other Amgen proprietary pharmaceutical compound or other product in existence on the Effective Date or developed after the Effective Date for treatment of any indication in the Licensed Field or the Option Field, and associated know-how.
Sample 1

Examples of Amgen Compound in a sentence

  • During the term of the Agreement, within thirty (30) days after determination by Amgen that any compound meets the definition of an Amgen Compound, NPS/Amgen Compound or Third Party Compound, such compound shall be designated by Amgen as an Amgen Compound, NPS/Amgen Compound or Third Party Compound, as the case may be.

  • For the avoidance of doubt, all bioanalytical work and results for the Combination, Ideaya Compound and Amgen Compound, including those of additional Sample studies conducted during the term of this Agreement are deemed Clinical Data.

  • Notwithstanding Section 10.1 (Joint Ownership and Prosecution), the Parties agree that all rights to Inventions to the extent relating solely to the Ideaya Compound, including any novel method-of-treatment and use involving the Ideaya Compound (and not the Amgen Compound), are the sole and exclusive property of Ideaya (the “Ideaya Sole Inventions”) and Amgen hereby assigns and agrees to assign all rights therein to Ideaya.

  • Profit for the fiscal year, such as it appears on the income statement, is constituted by the difference between the proceeds and the expenses for the fiscal year, following deduction for depreciations and provisions.

  • The JOC will attempt to reach decisions by consensus, except that Ideaya will determine in its sole discretion the dose and dosing regimen for the Ideaya Compound, and Amgen will determine in its sole discretion the dose and dosing regimen for the Amgen Compound.

  • Other than as may be agreed to by the Parties (including pursuant to this Section 2.7), this Agreement does not create any obligation on the part of Ideaya to provide the Ideaya Compound for any activities other than the Study, nor does it create any obligation on the part of Amgen to provide the Amgen Compound for any activities other than the Study.

  • Such vendor will provide the processed results of their bioanalytical work of such Samples to Amgen, a summary of which processed results will be included in the Final Study Report or similar report, along with the bioanalytical work of the Ideaya Compound and Amgen Compound performed by or on behalf of Amgen.

  • The Pharmacovigilance Agreement will include safety data exchange procedures governing the coordination of collection, investigation, reporting, and exchange of information concerning adverse experiences, pregnancy reports, and any other safety information arising from or related to the use of the Ideaya Compound and the Amgen Compound in the Study, consistent with Applicable Law and in accordance with the terms of the Pharmacovigilance Agreement.

  • In the event Amgen determines that in a country in the Territory a Third Party(ies) is selling a product [* * *] and Royalty(ies) due NPS from Amgen on Net Sales of such Non-Patented Amgen Compound in that country shall be calculated using a [* * *] percent [* * *] reduction of the rates set forth in Section 7.1(C)(1), for the period during which such product [* * *].

  • Amgen or a third-party vendor designated by Amgen will be responsible for overall bioanalytical work of Samples from Study subjects on the Combination or on either the Amgen Compound or Ideaya Compound separately as set forth in the Protocol.

Related to Amgen Compound

  • Licensed Compound means [***].

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Compounds means a small molecule HMT inhibitor.

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Licensed Product means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Covered Product The consumer product that You purchased concurrently with and is covered by this Agreement.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Drug Product means a specific drug in dosage form from a known source of manufacture, whether

  • Generic Product means a product which (a) contains as its active pharmaceutical ingredient a compound that is (or is substantially the same as) the Licensed Compound, and (b) has been placed on the market pursuant to a validly granted marketing authorization.